The porphyrias are a group of disorders of haem biosynthesis in which overproduction of haem precursors is associated with characteristic clinical features. Two main forms of clinical manifestation may occur together or separately: lifethreatening attacks of acute porphyria and photosensitization of the skin. I • 2 Because the porphyrias may present in ways that mimic other disorders, and because different types of porphyria share identical clinical features, accurate diagnosis depends on identifying patterns of haem precursor overproduction. This requires correct selection, performance and interpretation Mitochondrion identify patients with overproduction of haem precursors, if only to refer them elsewhere for full investigation.
BIOSYNTHESIS AND METABOLISM OF HAEM PRECURSORS
The pathway of haem biosynthesis is outlined in Fig. 1 . The porphyrinogen intermediates are unstable and readily autoxidize to porphyrins within tissues and after excretion.
In normal circumstances, most of the 5aminolaevulinate (ALA) produced is converted to haem. Only small amounts of intermediates are lost from the pathway and excreted either unchanged or after oxidation to porphyrins, the Cytosol SuccinylCoA + Glycine CD ® FIGURE 1. The pathway of haem biosynthesis, The reactions are catalysed by 5-aminolaevulinate (ALA) synthase (J), porphobilinogen (PBG) synthase (2) , PBG-deaminase (3) . uroporphyrinogen-Hl synthase (4) , uroporphyrinogen decarboxylase (5) , coproporphyrinogen oxidase (6) , protoporphyrinogen oxidase (7) and ferrochelatase (8) . In normal circumstances, less than 1% 0/ hydroxymethylbilane is cyclized non-enzymatically to uroporphyrinogen I.
of laboratory investigations. The extent to which patients with porphyria are investigated will vary according to local interest and expertise. As a minimum, all laboratories need to be able to This paper was prepared at the invitation of the Clinical Laboratory investigation Working Party of the Scientific Commiuee of the Association of Clinical Biochemists, but does not necessarily reflect their views.
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route of excretion being determined largely by the solubility of the compounds. Table I gives the concentrations of haem precursors in urine, faeces, plasma and erythrocytes.
THE DIFFERENT TYPES OF PORPHYRIA
The main types of porphyria are listed in Table 2 together with estimates of the prevalence of c1in- ically overt cases in the United Kingdom. Clinically indistinguishable attacks of acute porphyria occur in acute intermittent porphyria (AlP), hereditary coproporphyria (HC), variegate porphyria (VP) and in the recently described disorder, porphobilinogen (PBG)-synthase defi-ciencyy·6 In each of these disorders the liver is the main site of over-production of haem precursors and they are known collectively as the acute hepatic porphyrias. The clinical features of acute porphyria have been reviewed.' Almost all acute attacks start with severe abdominal pain, which may be accompanied by psychiatric abnormalities. Peripheral neuropathy develops in about 60% of patients. At least 75% of attacks are precipitated by drugs, alcohol, fasting or endocrine factors. I).) Acute attacks are commoner in women and are very rare in either sex before puberty. About 5% of those attacks that are severe enough to require hospitalization end Iatally." Skin lesions caused by photosensitization due to porphyrins occur in all types of porphyria except AlP and PBG synthase deficiency ( Table  2) . Porphyrin photosensitization produces two distinct clinical syndromes: acute photosensitivity on exposure to sunlight with erythema and oedema, which subside between acute episodes to leave either no visible changes or minimal scarring and thickening of the skin; and a syndrome in which subepidermal bullae, erosions caused by increased mechanical fragility, hypertrichosis and pigmentation occur in sun-exposed areas of the skin." The first of these is seen only in protoporphyria (PP), the second in all other cutaneous porphyrias. In VP and HC, acute attacks and skin lesions may occur together or separately.
Enzyme defects in the porphyrias
Each of the porphyrias listed in Table 2 results from a partial deficiency of one of the enzymes of haem biosynthesis (Table 3) .1,2.10.11 These enzyme deficiencies, with the exception of those that underlie some types of porphyria cutanea tarda (PCT), are inherited in either an autosomal dominant or recessive fashion ( Table 3 ). The inheritance and pathogenesis of PCT is complex.F'!' All patients have decreased hepatic uroporphyrinogen decarboxylase (EC 4.1.1. 37) activity. In about 15-20% of patients, this defect is also present in erythrocytes and other extrahepatic tissues and is inherited as an autosomal dominant trait (type II PCT; Table 3 ). In the remainder, the enzyme defect is restricted to the liver. Most of those patients have type I, or sporadic, PCT; the cause of the hepatic enzyme deficiency is unknown (Table 3) . Toxic PCT follows exposure to certain polyhalogenated aromatic hydrocarbons, notably hexachlorobenzene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. 13 In each type of porphyria, the rate of haem formation is maintained by a regulatory mechanism that increases the concentration of the substrate of the defective enzyme. 10,1 1 Intracellular accumulation and subsequent excretion of the substrate produces a pattern of plasma, erythrocyte and excretory abnormalities that is characteristic of that enzyme deficiency. The main features of the patterns that characterize each type of porphyria are shown in Table 4 .
Individuals who inherit the gene for one of the autosomal dominant porphyrias have quantitatively similar enzyme deficiencies, yet probably fewer than 10% ever develop symptoms. Thus in family studies, three types of enzyme-deficient individual can be identified: those with overt porphyria in whom symptoms are associated with overproduction of haem precursors, those with overproduction of haem precursors but no symptoms, and those without either symptoms or detectable overproduction of haem precur-sors. Individuals in the last two groups are said to have latent porphyria, although the term 'subclinical porphyria' may be used to indicate those with haem precursor overproduction. All Individuals who carry the gene for one of the autosomal dominant acute hepatic porphyrias (AlP, VP or HC) are at risk of developing acute attacks In response to drugs and other precipitants, although the risk is very low before puberty.
Latency may be a life-long state or follow a symptomatic phase. In PCT, urinary, faecal and plasma porphyrin concentrations may return to normal within a year or so of clinical remission. In AlP, VP and HC, evidence of haem precursor overproduction usually persists for many years after remission, but may eventually return to normal in some patients. For this reason, it may be very difficult to confirm or exclude a diagnosis of porphyria after prolonged remission, and every effort should be made to make a definite diagnosis while symptoms are present.
Clinical variants
In addition to the main types of porphyria listed in Table I , a number of clinical variants have been described. Most of these appear to be homozygous forms of the autosomal dominant porphyrias. Thus at least some patients with hepatoerythropoietic porphyria14 are homozygous for type II PCT. Homozygous forms of hereditary coproporphyria," variegate porphyria 16 and protoporphyria 17 have also been identified. All these cases have certain features in common: symptoms appear during childhood; enzyme activities are usually decreased by greater than 90%; and sustained overproduction of porphyrins occurs from an early age with increased erythrocyte protoporphyrin concentrations. The amount of porphyrin excreted may be no greater than in their autosomal dominant counterparts; excretion patterns are also similar. Identification is by enzyme assay. Measurement of erythrocyte porphyrin concentration provides a useful pointer to their existence" and should never be omitted when investigating porphyria in children or in those who have had symptoms since childhood.
The coexistence of other disorders may also modify expression. Kushner t Hexa-and pentacarboxylic porphyrins and coproporphyrin are increased to a smaller extent. Uroporphyrin is a mixture of type I and III isomers; heptacarboxylic porphyrin is mainly type III. Mixed porphyrias Very occasionally patients with porphyria may have porphyrin excretion patterns that suggest the presence of more than one enzyme defect. The co-existence of variegate porphyria and porphyria cutanea tarda, so-called 'dual porphyria', has been reported from South Africa" and a large family from Chester has been described in which there appears to be co-inheritance ofPBGdeaminase and protoporphyrinogen oxidase defects." In addition, more than one type of porphyria may occur independently in the same family."
HAEM PRECURSORS IN OTHER DISEASES
Increased concentrations of haem precursors may occur in a wide variety of other diseases." Four main types of abnormality are found: (i) Increased urinary excretion of ALA may occur in lead poisoning and, as an isolated abnormality, in hereditary tyrosinaernia." PBG excretion may rarely be increased in severe lead poisoning but always to a much lesser extent than ALA.
(ii) Coproporphyrinuri a may occur whenever hepatobiliary function is impaired. Decreased biliary excretion of coproporphyrin, particularly coproporphyrin I, leads to increased excretion in the urine. In addition, an increased concentration of coproporphyrin III in the urine may be found in lead poisoning and in some chronic alcoholics. The absence of increased concentrations of other urinary porphyrins together with normal faecal porphyrin concentrations distinguishes these causes of coproporphyrinuria from the porphyrias.
(iii) An increased total porphyrin concentration in erythrocytes is found in lead poisoning, iron deficiency and in sideroblastic and some other anameias. As in normal subjects, the porphyrin is predominantly zinc-protoporphyrin and, with the exception of lead poisoning, there are rarely any associated abnormalities of porphyrin excretion. Erythrocyte coproporphyrirr" or free protoporphyrin" may also be increased in rare forms of sideroblastic anaemia.
(iv) An increased concentration of dicarboxylic porphyrins in faeces is occasionally found as an isolated abnormality when investigating suspected porphyria. The dicarboxylic porphyrin fraction of faeces contains protoporphyrin and other dicarboxylic porphyrins (meso-, deutero-, pempto-porphyrins) derived from it within the gut by bacterial reduction or removal of vinyl substituents." The protoporphyrin may be of metabolic origin or may come from protohaem derived from haemoglobin and other haemoproteins that enter the gut through normal processes, in the diet or as the result of bleeding into the gastrointestinal tract. Even minor degrees of gastrointestinal haemorrhage, particularly those occurring high in the gut and which may not be associated with positive tests for occult blood, can markedly increase the concentration of dicarboxylic porphyrins in faeces. The dicarboxylic porphyrins derived from protoporphyrin by bacterial action are less ether-soluble than protoporphyrin and may be incorrectly identified as 'coproporphyrin' by the solvent extraction techniques" that are widely used to measure faecal porphyrins. The faecal porphyrin concentration is also diet-dependent and dietary oddities, for example, excessive consumption of brewer's yeast," may produce potentially misleading abnormalities. Porphyria can be excluded as the cause of an increased faecal dicarboxylic porphyrin ('protoporphyrin') fraction by showing that there is no accompanying increase in either coproporphyrin in faeces or free protoporphyrin in erythrocytes.
LABORATORY INVESTIGATIONS
Patients with porphyria present in a bewildering variety of ways. In most hospitals the diagnosis is suspected far more frequently than it is confirmed. All hospital laboratories need to have a set of reasonably simple tests that can be used to distinguish the few that have porphyria from the many who do not. This set of investigations should include tests capable of detecting increased urinary excretion of PBG and porphyrins, and increased concentrations of porphyrins in faeces, whole blood and, ideally, in plasma or serum. Suitable first-line tests are described below. Further investigations are then required to confirm the diagnosis and establish the type of porphyria.
Specimen collection
Porphyrins are reasonably stable in solution, provided they are protected from light and oxidants. PBG is less stable and, particularly in acid solution, rapidly polymerizes to uroporphyrin and a brownish-red pigment, porphobilin.
Fresh random samples of urine (about 25 mL) are more suitable than 24 h collections for the diagnosis of porphyria. The latter inevitably postpone analysis and diagnosis rarely depends on abnormalities that are revealed only by timed collections. Urine should be analysed for PBG and porphyrins as soon as practicable, though concentrations are unlikely to change sufficiently within 36 h to produce an incorrect diagnosis, particularly if the urine is kept at neutral pH in the dark at 4°C. 30 Longer storage is best carried out at -20°C, if necessary after adjusting the pH to 7·0-7·5 with sodium bicarbonate." Urine samples that appear very dilute (creatinine concentration less than 4mmolJL) are not suitable for analysis.
About 5 g wet weight of faeces is adequate for determination of porphyrin concentrations. Ideally, porphyrins in faeces should be analysed within a few hours of collection. However, if delay is unavoidable, diagnostically significant changes are unlikely to occur within 36 h at room temperature and samples are stable for many months at -20°C.
Blood samples, anticoagulated with EDTA and kept in the dark, show no loss of protoporphyrin for up to 8 days at room temperature and for up to 8 weeks at goC or lower."
Porphyrin precursors
Porphobilinogen Detection and measurement of PBG is based on its reaction with p-dimethylaminobenzaldehyde in HCI (Ehrlich's reagent) to give a red compound. Modifications of the Watson-Schwartz
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test 32 ,13 or the Hoesch test" are widely used to screen for excess PBG in urine. A simple procedure which has a lower limit of detection of about 35-50 umolj]; for PBG is described in the Appendix. Chloroform should not be used as the only solvent in the Watson-Schwartz test." It is a less effective extractant than butan-l-ol or amyl alcohol and its use is an important cause of false positive tests. Because urine may contain substances that inhibit or mimic the PBG-Ehrlich aldehyde reaction, quantification of PBG requires prior purification by anion-exchange chromatography." The Bio-Rad PBG-Test (Bio-Rad Laboratories Ltd, Watford, UK), which includes technical instructions, provides a convenient method. Low concentrations of PBG are more accurately measured if 2·0 mL of urine, rather than the O· 5 mL recommended by the manufacturers, is used. Identity of the PBG-Ehrlich complex should be confirmed by spectrophotometry ( Fig. 2) .
5-Aminolaevulinic acid
There is no simple screening test for excess ALA in urine. Methods for the measurement of ALA depend on condensation of ALA with acetylacetone or ethyl acetoacetate to form a pyrrole that reacts with Ehrlich's reagent and require prior chromatography to separate ALA and PBG and to concentrate ALA ls (Bio-Rad ALA-TEST, Bio-Rad Laboratories Ltd).
Porphyrins
Urine, faeces and other biological samples contain mixtures of porphyrins of varying complexity. Identification of the main components is essential for the accurate diagnosis of porphyria but usually requires time-consuming procedures. Assessment of total porphyrin concentration can be carried out more rapidly and is all that is required as a first-line test (see Appendix).
Porphyrins have characteristic electronic absorption spectra with an intense maximum around 400 nm that is known as the Soret peak.i:" For porphyrins of clinical significance, Soret maxima in acid solution range from 398 nm to 407 nm and have molar absorption coefficients of 262-541 x IO'Iitre . mol r " : ern -I. Irradiation at wavelengths around the Soret maximum produces an intense red fluorescence with emission maxima around 600 nm that vary for different porphyrins and depend on the nature of the solvent." This property enables low concentrations of porphyrin (around I Jlmol/L) to be detected in solution by direct inspection in long wavelength ultraviolet light, fluorescence being most intense in acid solution. For measurements of porphyrin fluorescence, fluorometers should be fitted with a red-sensitive photomultiplier and ideally should be capable of giving a full-scale deflection when calibrated with 10 nmoljL coproporphyrin in 1·5 M HCI.
All porphyrins of clinical significance are readily extracted into polar organic solvents (butan-I-ol, amyl alcohol) from aqueous solutions adjusted with acetic acid to around pH 3'5, which is close to their iso-electric points. Extraction into less polar solvents, such as ether or ethylacetate, also requires the presence of acetic acid, solubility being determined by the nature of the side chains, particularly the number of acidic groups. Thus uroporphyrin is insoluble in ether, while mixtures of other porphyrins can be fractionated by extraction from ether or ethyl acetate with different concentrations of HCl.l.28.l6
First-line tests
Urine. Qualitative screening tests for increased urinary porphyrin excretion based on solvent extractiorrf:" are insensitive and subject to interference by compounds that quench or obscure porphyrin fluorescence.':" They should be replaced as first-line tests by quantitative spectrophotometric or fluorometric methods. Whichever method is used, it is important to ensure that the acid-soluble precipitates that may form in alkaline urine, and which adsorb porphyrins, are redissolved during analysis.
The total porphyrin concentration can be measured directly in acidified urine by first" or second derivative" spectroscopy or in diluted urine by fluorornetry'":" or derivative synchronous fluorescence spectroscopy." Removal of interfering substances and concentration of porphyrins by anion exchange chromatography before spectroscopy" is more time-consuming and probably not suitable as a first-line test in a general laboratory. Direct spectrophotometry of acidified urine, although useful when porphyrin concentrations are sufficiently increased to allow substantial dilution, has been criticized as a first-line test because urine contains other compounds that absorb in the Soret region. However, provided the spectrum is determined around the Soret maximum, this does not appear to be a problem in practice.F'"
If suitable equipment is available, the first-line tests that combine simplicity and accuracy to the greatest extent are first-derivative spectroscopy" and spectrofluorometry of acidified urine. 40 • 41 For other laboratories, a direct spectrophotometric method" such as that described in the Appendix is recommended.
Faeces. Faeces frequently contain red-fluorescent pigments derived from dietary chlorophyll which.must be removed before assessing the concentration of porphyrins in faecal extracts. A number of qualitative screening tests based on solvent extraction have been described.28.4s. 46 The test outlined in the Appendix is useful for rapid exclusion of increased faecal porphyrin concentrations. However interpretation is subjective and until considerable experience has been gained, it is wise to carry out quantitative measurements in parallel. The spectrophotometric method for the measurement of total ether-soluble porphyrins described by Lockwood et al." is adequate for this purpose. However, this test is not suitable for use in circumstances where a diagnostic increase in the concentration of an individual porphyrin may occur within the range of total ether-soluble porphyrin concentrations found in normal individuals.
Whole blood. Methods of screening for increased erythrocyte porphyrin concentrations using either a solvent extraction procedure or fluorescence microscopy have been described." In practice, false negative results are not infrequent with either type of screening test and all negative, as well as all positive results, should be confirmed by measurement of erythrocyte porphyrins. A quantitative method should therefore replace these screening techniques as the first-line investigation of choice.
A number of fluorometric micromethods that measure total porphyrins in 2-50 JlL blood are sufficiently rapid and simple for this purpose.":"
Diagnostic tests
Definitive diagnosis of all types of porphyria requires quantification with identification of individual porphyrins and porphyrin precursors in urine and faeces (Table 4 ). Urinary and faecal porphyrin mixtures may be separated into fractions by solvent partition techniques or into individual components by TLC or HPLCyul TLC. A number of TLC systems that readily separate the methyl ester derivatives of porphyrins according to the number of acidic side chains, and separate isocoproporphyrin from coproporphyrin, have been described.' Figure 4 shows typical patterns obtained by applying porphyrin methyl esters dissolved in chloroform to a Kieselgel 60 (E. Merck, Darmstadt, Germany) TLC plate (20 x 20cm) which was developed with toluene: ethylacetate: ethanol (80: 15:3, by vol)." HPTLC Kieselgel 60 plates (\0 x \Oem) Solvent partition methods. These techniques make use of the partition of porphyrins between diethyl ether, aqueous solutions at pH 3-4 and different concentrations of HCI to divide urinary porphyrins into coproporphyrin and uroporphyrin fractions, and faecal porphyrins into protoporphyrin, coproporphyrin and ether-insoluble porphyrin fractions.':" Standard methods are described by Moore." Determination of the ether-insoluble porphyrin fraction of faeces, including X porphyrin, 52 is rarely necessary for diagnostic purposes.
Plasma. A rapid screening method for the detection of increased concentrations of porphyrin in plasma by fluorescence emission spectroscopy has been described by Poh-Fitzpatrick." Plasma, diluted \O-fold with phosphate-buffered saline, is scanned in a recording spectrofluorometer (excitation at 405 nm, scan from 570-650 nm). Increased concentrations of coproporphyrin and uroporphyrin give a peak at about 615 nm, and protoporphyrin at about 632 nm, while a protein-bound porphyrin found only in variegate porphyria has a peak at 623-626 nm (Fig. 3) .
These micromethods use an acid extraction procedure that removes the zinc from zinc-protoporphyrin. Since distinction between zincprotoprophyrin and free porphyrin is important for the diagnosis of PP, all samples with an increased total porphyrin concentration should be further investigated using a neutral extractant, such as ethanol" (see Appendix). give excellent resolution within 15min. Simple procedures for the extraction and esterification with merhanol-Hj Sfs, (5 or 10%. v/v) of urinary and faecal porphyrins have been published. 3 . 4 . 5 1. 53.54 Quantitative data can be obtained from TLC plates by fluorescence scanning" or by spectrophotometry after elution with chloroform-methanol (4: I. vlv). However the patterns are usually so distinctive as to make this unnecessary ( Fig. 4 ).
HPLC. In recent years. a large number of methods have been developed for the separation of porphyrin methyl esters by HPLC and of porphyrins by reverse-phase (RP) HPLC. 51 The ammonium acetate buffer-organic modifier RP-HPLC systems developed by Lim and coworkers":" are robust and provide complete resolution of urinary and faecal porphyrin mixtures. including separation of type I and III isomers. Prior extraction of faecal porphyrins is required. for example as described by Lockwood et al. 4 Urine may be injected directly onto the RP-HPLC column. although preliminary extraction and concentration may be required for low concentrations unless f1uorometric detection is used.i':"
Choice of method. Choice will be influenced by availability of equipment and expertise. As the porphyrias are uncommon disorders. many laboratories may find it convenient to refer samples (or patients) to specialized centres for diagnostic tests. Solvent partition methods are reasonably straightforward and do not require authentic porphyrin standards or special equipment. However. they are time-consuming. separation between porphyrins may be poor. the fractions are usually mixtures and. on occasions. even the main component may not be identified accurately. For example. isocoproporphyrin and bacterial metabolites of protoporphyrin may be analysed as 'coproporphyrin', In addition. distinction between PCT. VP and the adult onset form of congenital erythropoietic porphyria (CEP) may occasionally be difficult. leading to mis-classificauon.":" These problems are avoided if porphyrins are fractionated by TLC or HPLC.
For most diagnostic purposes. separation by either TLC or HPLC is satisfactory. HPLC provides high resolution and quantification of individual porphyrins and is currently the preferred method for the separation of isomers" but requires expensive. dedicated equipment. On the other hand. TLC is relatively cheap. may be less time-consuming. and provides simpler-but still diagnostic-separation patterns.
Enzyme measurements
Measurement of the enzymes of haem biosynthesis is rarely essential for the accurate diagnosis of overt porphyria. Enzyme assays are mainly useful for the detection of latent porphyria in families and for the establishment of a diagnosis retrospectively. These aspects. which are discussed below. are better restricted to specialised centres which have accumulated sufficient experience to provide the necessary background for interpretation.
SELECTION OF TESTS
There are four main clinical situations in which the laboratory will be asked to investigate patients for suspected porphyria. Each requires a different approach and will be discussed separately. Correct selection and interpretation of investigations is therefore critically dependent on knowledge of the clinical features.
Suspected acute porphyria
Acute abdominal pain is a prominent feature of the acute attacks that occur in AlP, VP, HC and PBG-synthase deficiency, and it is common practice for patients with unexplained abdominal pain to be investigated for porphyria. Most patients in this group do not have porphyria.
The key investigation is examination of urine for excess PBG. It is impossible to prove that symptoms are caused by acute porphyria unless concurrent overproduction of PBG (or ALA in PBG-synthase deficiency) can be demonstrated. For patients known to have latent porphyria, absence of an increase in PBG excretion when symptoms are present suggests that these are likely to be due to some other cause.
First, the qualitative screening test for PBG described in the Appendix should be carried out using a fresh, random sample of urine. This test is almost always positive during an acute attack.P'" If the screening test is positive, increased PBG excretion must be confirmed by a specific, quantitative method as false positives occur occasionally. In patients with increased PBG excretion, urinary porphyrin analysis has little diagnostic value; the distinction between AlP, VP and HC is made by faecal porphyrin measurements (Table 4 ). Normal total faecal porphyrin concentration confirms the diagnosis of AlP; measurement of erythrocyte PBGdeaminase (EC 4.3.1.8) activity is not essential for this purpose but is a necessary starting point for family investigation. Total faecal porphyrin excretion is normally increased many fold in both acute VP and HC; differentiation is by measurement of individual porphyrins (Table 4 ). Faecal porphyrin concentrations may be increased to a small extent in some patients with AlP, and may be decreased to similar levels in those rare patients in whom acute VP is complicated by cholestatic jaundice. If there is any doubt, the
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conditions can be distinguished by fluorescence emission spectroscopy of plasma50 (Table 4) . A negative screening test for PBG decreases the probability of, but does not exclude, acute porphyria." The urine may contain inhibitory or interfering compounds which produce a falsenegative test" or the PBG concentration may be raised but below the detection limit of the screening test. In VP and HC, but only very rarely in AlP, PBG excretion may fall rapidly and return to normal within a few days of the onset of an acute attack. If clinical suspicion of porphyria persists, it is essential to quantify PBG and ALA in urine, and to measure the total porphyrin concentration of urine and faeces. If none of these tests reveal any abnormality, the probability of any form of acute porphyria becomes so low as to exclude it for practical purposes. Measurement of haem biosynthetic enzymes is not especially helpful in this situation. Normal erythrocyte PBG-deaminase activity adds to the evidence against AlP, but does not exclude it." Decreased activity, in the absence of PBG overproduction, does not prove that symptoms are caused by AlP and may be difficult to interpret as little is known about erythrocyte PBGdeaminase activity in severe non-porphyric illness. Measurement of the defective enzymes in VP and HC is technically demanding, requires nucleated cells, such as lymphocytes, Iymphoblasts or fibroblasts, and produces similar interpretative problems.
Two abnormalities that are occasionally found in patients being investigated for acute abdominal pain may become diagnostic problems. First, an increase in urinary porphyrin concentration, without any increase in PBG excretion or faecal porphyrin concentration, may occur. Identification of the type of porphyrin by TLC or HPLC is then required. If it is coproporphyrin, the patient has coproporphyrinuria. Consideration of the clinical history, liver function tests and haematological status is usually sufficient to determine the cause. Blood lead, erythrocyte porphyrin and PBG-synthase (EC 4.2.1.24) measurements may very occasionally be required to confirm or exclude lead poisoning or PBG-synthase deficiency (Table 4 ). Less frequently, increased excretion of uroporphyrin and other acetic acid substituted porphyrins will be found. The presence of porphyrins, other than coproporphyrin, raises the suspicion of porphyria and requires detailed further investigation (see below).
Secondly, normal urinary PBG and porphyrin concentrations but increased faecal porphyrin excretion may be found. Fractionation of the faecal porphyrins by TLC or HPLC (solvent partition is unsuitable for this purpose) usually reveals that only the dicarboxylic porphyrin fraction is increased, suggesting an origin from protohaem entering the gut in the diet or through haemorrhage. A test for occult blood may be positive but a negative result does not exclude this cause of an increased faecal porphyrin concentration. An accompanying increase in coproporphyrin, or an increase in coproporphyrin alone, suggests the possibility of VP or HC, respectively. Detailed investigation, including fluorescence spectroscopy of plasma, combined with enzyme measurements and family studies may be required before a final diagnosis is made. To avoid diagnostic errors, samples of urine, faeces and blood should be obtained from all patients. The most useful first-line tests are measurement of total urinary porphyrin concentration, qualitative screening for increased total faecal porphyrin concentration and fluorescence emission spectroscopy of plasma. If all three tests are normal in a patient with active PCT-type skin lesions, it is very unlikely that the skin lesions are caused by porphyria. Patients with PCT who are in, or entering, clinical remission may have urinary and faecal total porphyrin concentrations within normal limits, yet still have Acute photosensitivity Protoporphyria is an uncommon but important cause of acute photosensitivity that is difficult to distinguish clinically from commoner causes of photosensitivity.
Because most patients presenting with acute photosensitivity will not have PP, it is important to use a first-line test that does not give falsenegative results. For this reason, the first test in this group should be measurement of total blood porphyrin using one of the fluorometric micromethods described above (see Appendix). When suitable equipment is not available locally, samples should be referred appropriately. If the total porphyrin concentration is increased, the ratio of free to zinc-chelated protoporphyrin should be determined (Fig. 5) . A predominant increase in free protoporphyrin confirms the diagnosis ofPP. No further tests are required for diagnosis (Table 4 ), although measurement of plasma and faecal porphyrins may be useful for management and assessment of the likelihood of development of complications, such as liver disease."
PCT-type skin lesions
This group contains the commonest type of porphyria, PCT, and all other cutaneous porphyrias except PP. Because of their characteristic skin lesions, these disorders can usually be distinguished clinically from other dermatological conditions, with the exception of the pseudoporphyria that may be caused by drugs, particularly naproxen, or complicate chronic renal failure." Thus, patients referred by an experienced dermatologist for investigation are likely to have porphyria. (Table 4 ; Fig. 4 ). At least 50% of patients with VP in the United Kingdom present with skin lesions unaccompanied by any evidence of acute porphyria. Differentiation from PCT requires measurement of faecal and plasma porphyrins (Table 4 ). In recent years an adult onset form of CEP, that is clinically indistinguishable from PCT, has been described." These patients have the characteristic urinary and faecal porphyrin patterns of CEP with increased erythrocyte porphyrin concentrations (Table 4 ). Confirmation of diagnosis requires isomer analysis to show that the excreted porphyrins belong to the type I series.
Diagnosis in this group of disorders should never be based on urinary porphyrin analysis alone, even when patterns are determined by TLC or HPLC. Unless faecal and blood specimens are examined, the form of VP known as 'dual' porphyria" may be misdiagnosed, and the adult form of CEP mistaken for PCT. Very occasionally a PCT-like syndrome results from overproduction of porphyrins by a hepatic tumour. This condition should be considered in the differential diagnosis ofPCT, especially if the porphyrin excretion pattern is atypical."
In children with PCT-type skin lesions, and in adults in whom porphyria started in childhood, measurement of erythrocyte porphyrins should never be omitted. Apart from the classical form of CEP, which usually presents in infancy, such patients may have type II PCT, hepatoerythropoietic porphyria or other homozygous forms of porphyria, in which erythrocyte porphyrin concentrations are abnormal." The distinction
Investigation of the porphyrias 407
between these conditions and their autosomal dominant counterparts requires appropriate enzyme assays.
Latent porphyria
Investigation of asymptomatic individuals for latent and subclinical porphyria is required either to detect gene carriers amongst the relatives of a patient known to have a particular type of porphyria, or to confirm or refute a diagnosis of porphyria (often of unspecified type) long after the initial illness. Each requires a different approach, and may require special investigations outside the scope of many laboratories.
Family studies
The importance of investigating relatives of patients with AlP, VP and HC can hardly be overemphasized. Every effort should be made to identify gene carriers before they develop symptoms so that they can be warned to avoid known precipitants of acute porphyria.' Strategies for detecting latent porphyria are different for each disease, being influenced by the current availability and complexity of measurements, but all are constrained by the observation that gene carriers very rarely show any evidence of haem precursor overproduction until after puberty. AlP is genetically heterogeneous." At least 90% of patients have mutations that decrease PBG-deaminase activity in all tissues. 58.63 In these families measurement of erythrocyte PBGdeaminase activity is currently the most effective method for detecting gene carriers. 58.64 However, because there is some overlap between enzyme activities in normal subjects and AlP patients,58.64.65 an unequivocal assignment of status cannot be made for all relatives, even when gene dosage," measurement of ALA-synthase activity" and PBG excretion is taken into account. Erythrocyte PBG-deaminase activity is very dependent on the age distribution of circulating erythrocytes. For this reason, measurements are not useful before the age of 6-8 months or in individuals who are haematologically abnormal. As for carrier detection in other inherited disorders, assay results should be used to calculate the posterior probability of carrying the gene for AlP at the individual's prior genetic risk. 65.67 Few laboratories have collected sufficient data to employ this approach; and there is little published information about the precision and performance of PBG-deaminase assays over the periods of time required to collect it. In general, carrier detection is easier than carrier exclusion, but the situation is likely to improve now that restriction fragment length polymorphisms have been identified within the PBG-deaminase gene 67 • 68 and shown to be informative in some AlP families. 67 • 68 The same approach is likely to improve identification of latent porphyria in the small number of AlP families in which the mutation is not expressed in erythrocytes.t':" Identification of carriers of the genes for VP or HC is more difficult. Assays for protoporphyrinogen oxidase (EC 1.3.3.4) and coproporphyrinogen oxidase (EC 1.3.3.3) are complex and, because both enzymes are mitochondrial, require nucleated cells. In adult relatives of patients with VP, the plasma should be scanned by fluorescence emission spectroscopy and the faecal porphyrins measured. Individuals with the characteristic 'VP porphyrin' peak in their plasma and unequivocally increased protoporphyrin and coproporphyrin concentrations in their faeces are carriers; no further investigation is needed. Urinary PBG and porphyrin excretion are usually normal in carriers and urinary measurements are not useful for family studies. Protoporphyrinogen oxidase assays should be restricted to potential carriers carriers who are children, or adults with normal or equivocal porphyrin measurements. A similar approach is required for He, except that plasma measurements are less useful. Coproporphyrin (not total porphyrin) is measured in faeces and coproporphyrinogen oxidase in those with normal or equivocal findings.
Family studies are not essential for the management of PP or PCT but may occasionally be requested. Measurement of erythrocyte free protoporphyrin will detect some asymptomatic carriers of the PP gene, but assay of ferrochelatase (EC 4.99. 1.1) activity is required for those with normal porphyrin concentrations." Probably less than 10% of carriers of the PP gene ever develop symptoms" and the factors that determine onset of symptoms are not understood. In PCT, measurement of erythrocyte uroporphyrinogen decarboxylase differentiates type I from type II and detects latent type II PCT. IJ
Other diagnostic problems
Occasionally laboratories are asked to exclude the possibility of AlP, VP or HC as the cause of a chronic neurological or psychiatric disorder some time after the initial illness that has suggested the diagnosis." In such cases, the probability of porphyria is low, and the demonstration of normal urinary PBG and faecal porphyrin concentrations by quantitative methods should be sufficient.
A more difficult problem is presented by asymptomatic individuals who have been told, often many years before, that they have porphyria. They now require investigation, either because the original diagnosis is being questioned or because relatives wish to be investigated and the type of porphyria is unknown. The first step is to quantify PBG and porphyrins in urine, porphyrins in faeces and erythrocytes and to determined the fluorescence emission spectrum of the plasma. These investigations may produce a diagnosis but in our experience often do not. However, absence of any evidence for haem precursor over-production, even on repeated investigations, does not overturn the original diagnosis. After long periods of remission, usually many years, haem precursor excretion may occasionally return to normal in AlP, VP or HC, while complete biochemical remission is frequent in PCT. In such individuals it may be very difficult to obtain a definite diagnosis, even after extensive investigation, including enzyme assays, of first degree relatives in addition to the patient.
CONCLUSION
The porphyrias are uncommon disorders that require specialized investigation for precise diagnosis. Every effort must be made to establish an accurate diagnosis during the presenting illness; retrospective diagnosis may be very difficult. Samples (or patients) may need to be referred to a laboratory with special expertise in the diagnosis of porphyria.
All laboratories should be able to identify acute porphyria. The urinary and faecal tests described in the Appendix represent the minimum that is required for this purpose. A method for the quantification of PBG (the BioRad kit is recommended) should also be available either locally or through referral to a specialist laboratory.
The cutaneous porphyrias are chronic disorders. The tests described in the Appendix will identify the overproduction of porphyrins that is associated with the active phase of these disorders. If spectrofluorometric methods for examining erythrocyte porphyrins cannot be performed locally, blood samples from patients with acute photosensitivity must be referred to a specialist laboratory.
Identification and measurement of individual porphyrins is required for determination of the type of porphyria. Urine analyses alone are not sufficient for this purpose. Diagnostic errors may be made unless faecal and blood porphyrins are also examined. TLC or HPLC methods should now replace solvent extraction techniques for the fractionation of mixtures of porphyrins. Identification of the type of porphyria should be carried out by a specialist laboratory.
Relatives of patients with AlP, VP and HC must be investigated for latent porphyria. The detection of latent forms of these and other porphyrias requries special techniques and is best carried out by reference laboratories.
APPENDIX

Recommended first-line tests for screening for porphyria
Porphobilinogen in urine Mix urine (2 mL) with Ehrlich's reagent (2,8 g p-dimethylaminobenzaldehyde/L of 7 M-llCI) (2 mL), allow to stand for 2 min, add saturated sodium acetate (4mL), mix, add amyl alcohol (2 mL) or butan-l-ol (2 mL), mix vigorously and allow the phases to separate. If any red colour remains in the aqueous (lower) phase, remove and discard the upper phase and repeat the extraction procedure until the organic phase is colourless. If, at this stage, the aqueous phase is red, or even faintly orange in colour, the test is positive. All positive tests must be confirmed by specific, quantitative measurement of PBG (see text).
The extraction procedure distinguishes the red compound formed with PBG, which appears on addition of Ehrlich's reagent and is not extracted by the organic solvent, from that produced by urobilinogen, which develops slowly, especially after addition of sodium acetate, and is soluble in butan-I-o!. A control test in which Ehrlich's reagent is replaced by 7M-HCl detects red indicator dyes which occasionally appear in urine after ingestion of colouring agents in medicines, sweets, soft drinks or various foodstuffs.
Porphyrin in urine, faeces or erythrocytes
Exposure to strong light should be avoided during analytical procedures and all organic solvents should be peroxide-free. Analytical reagent grade ether contains less than 0·15 J1g/g ether peroxide and may be used without purification.
Investigation of the porphyrias 409
For detection of red fluorescence due to porphyrins, aqueous acid solutions should be examined in light from an ultraviolet lamp fitted with a Wood's filter (maximum trasmission around 365 nm). The lamp needs to be sited in a darkened room or area of the laboratory and the solution must be inspected against a black background to detect low intensities of fluorescence.
Total urinary porphyrin (43) . After mixing to resuspend any precipitate, 4 mL of urine is mixed with concentrated (11,6 M) HCI (1'0 mL). When all acid-soluble material has dissolved, the mixture is scanned on a recording spectrophotometer between 350 and 450 nm. Urine samples that contain acid-insoluble suspended material must be clarified by filtration or centrifugation before scanning. The absorbance (A) of any absorption peak in the Soret region is measured as shown in Fig. 2 and the approximate porphyrin concentration calculated:
Porphyrin concentration (nmol/L) = A x 2016 x 1·25
The factor 2016 is derived from the molar absorption coefficients of coproporphyrin and uroporphyrin in HCl and assumes that these porphyrins are present in the proportion 7: 1 43 ;
1·25 is a dilution factor. The method is not suitable for very dilute urine (creatinine less than 4 mmol/L), Total faecal porphyrin. A pea-sized sample of faeces (liquid samples are not suitable for analysis) is extracted with glacial acetic acid (0'5 mL) by grinding with a glass rod or vigorous vortex mixing. The resulting suspension is mixed throughly with diethyl ether (5 mL), centrifuged and the supernatant decanted into a thin-walled glass tube, and 1'4M-HCl (0'5mL) is added to the supernatant. After vigorous vortex mixing for 20 s, the phases are allowed to separate and the lower acidic phase is examined for red fluorescence. A faint pink to intense red fluorescence in the lower phase indicates the presence of porphyrins; the intensity being proportional to the porphyrin concentration. Red fluorescent pigments derived from chlorophyll remain in the upper phase.
This test is sufficiently sensitive to detect porphyrin concentrations in the upper normal range. Absence of fluorescence in the lower phase indicates that the faecal porphyrin concentration is not increased.
The concentration of total ether-soluble porphyrins should be measured in all samples that show either any red-pink fluorescence, or bluegreen fluorescence sufficiently intense to mask porphyrin fluorescence, in the lower acid phase by using the simple method described by Lockwood et al' With this method, porphyrin concentrations are expressed per gram dry weight of faeces. Each laboratory needs to determine its own reference range using a carefully standardized method for drying faeces.
It is recommended that both the above tests are carried out on all samples until sufficient experience has been gained to allow the qualitative test alone to be used to rapidly identify samples with normal faecal porphyrin concentrations.
Total blood porphyrin. EDTA-anticoagulated whole blood (0'02 mL) is diluted with saline, extracted with ethylacetate:acetic acid and porphyrin is separated from haem by back-extraction into H'Cl before fluorometric measurement of porphyrin concentration, exactly as described by Piomelli (1977) 48 ('direct FEP test'). If sample and reagent volumes are scaled down fourfold, the extractions can be carried out in a polypropylene tube (1' 5 mL Eppendorf; Sarstedt Ltd, Leicester, UK) and the precipitated blood proteins sedimented by centrifugation (12-15000g, 5 min) without the addition of celite.
If the total porphyrin concentration is increased, the proportion of zinc-protoporphyrin to protoporphyrin should be assessed. EDTAanticoagulated blood (0'05 mL) is haemolysed by mixing with 0·2 mL of water. Haemolysate (0'05mL) is added to ethanol.HyO (19:1, viv) 1·0 mL) and immediately vortex mixed. After centrifugation, the supernatant, which should be almost colourless, is scanned in a spectrofiuorometer (excitation 415 nm) from 550-670 nm to determine the emission spectrum. The presence of a major peak at 587 nm (zinc-Protoporphyrin) excludes PP (Fig. 5 ).
